Clinical Trial
doi: 10.1001/jama.2017.1840.
Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months
Affiliations
- PMID: 28444267
- DOI: 10.1001/jama.2017.1840
Item in Clipboard
Clinical Trial
Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months
JAMA.
.
No abstract available
Similar articles
-
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Hum Vaccin Immunother. 2015;11(7):1689-702. doi: 10.1080/21645515.2015.1050570. Hum Vaccin Immunother. 2015. PMID: 26062002 Free PMC article. Clinical Trial.
-
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV.Pediatr Infect Dis J. 2018 Jun;37(6):595-597. doi: 10.1097/INF.0000000000001874. Pediatr Infect Dis J. 2018. PMID: 29278613
-
Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Hum Vaccin Immunother. 2016;12(1):30-8. doi: 10.1080/21645515.2015.1058458. Epub 2015 Jul 25. Hum Vaccin Immunother. 2016. PMID: 26211489 Free PMC article. Clinical Trial.
-
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000. BioDrugs. 2011. PMID: 21942919 Review.
-
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Pediatr Infect Dis J. 2015. PMID: 26107345 Review.
Cited by
-
Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials.Front Public Health. 2023 Sep 21;11:1152057. doi: 10.3389/fpubh.2023.1152057. eCollection 2023. Front Public Health. 2023. PMID: 37808981 Free PMC article. Review.
-
Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis.Vaccines (Basel). 2020 Oct 20;8(4):618. doi: 10.3390/vaccines8040618. Vaccines (Basel). 2020. PMID: 33092049 Free PMC article. Review.
-
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.Papillomavirus Res. 2020 Dec;10:100203. doi: 10.1016/j.pvr.2020.100203. Epub 2020 Jul 11. Papillomavirus Res. 2020. PMID: 32659510 Free PMC article. Clinical Trial.
-
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479. Cochrane Database Syst Rev. 2019. PMID: 31755549 Free PMC article.
-
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.Clin Infect Dis. 2020 Aug 14;71(4):1022-1029. doi: 10.1093/cid/ciz887. Clin Infect Dis. 2020. PMID: 31617568 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
